FDA
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
-
-
-
-
-
-
-
UBS Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
-
-
-
-
-
-
-
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

